[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SRP9

Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain -
Function

Signal-recognition-particle assembly has a crucial role in targeting secretory proteins to the rough endoplasmic reticulum membrane. SRP9 together with SRP14 and the Alu portion of the SRP RNA, constitutes the elongation arrest domain of SRP. The complex of SRP9 and SRP14 is required for SRP RNA binding.

> Gene Ontology
 
Biological Process GO:0006414 translational elongation
GO:0006417 regulation of translation
GO:0006448 regulation of translational elongation
GO:0006612 protein targeting to membrane
GO:0006613 cotranslational protein targeting to membrane
GO:0006614 SRP-dependent cotranslational protein targeting to membrane
GO:0006616 SRP-dependent cotranslational protein targeting to membrane, translocation
GO:0010608 posttranscriptional regulation of gene expression
GO:0017148 negative regulation of translation
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0045047 protein targeting to ER
GO:0045900 negative regulation of translational elongation
GO:0065002 intracellular protein transmembrane transport
GO:0070972 protein localization to endoplasmic reticulum
GO:0071806 protein transmembrane transport
GO:0072599 establishment of protein localization to endoplasmic reticulum
GO:0072657 protein localization to membrane
GO:0090150 establishment of protein localization to membrane
Molecular Function GO:0005047 signal recognition particle binding
GO:0008312 7S RNA binding
GO:0043021 ribonucleoprotein complex binding
Cellular Component GO:0005785 signal recognition particle receptor complex
GO:0005786 signal recognition particle, endoplasmic reticulum targeting
GO:0005791 rough endoplasmic reticulum
GO:0030867 rough endoplasmic reticulum membrane
GO:0048500 signal recognition particle
> KEGG and Reactome Pathway
 
KEGG hsa03060 Protein export
Reactome R-HSA-74160: Gene Expression
R-HSA-392499: Metabolism of proteins
R-HSA-1799339: SRP-dependent cotranslational protein targeting to membrane
R-HSA-72766: Translation
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SRP9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SRP9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SRP9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2680.348
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.230.946
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2980.903
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2790.339
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2160.908
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3590.88
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1580.745
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3970.862
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1090.966
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.310.894
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0930.98
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0810.3
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SRP9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SRP9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SRP9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SRP9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SRP9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SRP9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SRP9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSRP9
Namesignal recognition particle 9kDa
Aliases signal recognition particle 9kD; Signal recognition particle 9 kDa protein
Chromosomal Location1q42.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SRP9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.